Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen
{"title":"The effects of cognitive behavioral therapy for insomnia in patients with cardiovascular disease: a systematic review and meta-analysis.","authors":"Silje Glenna Andersen, Henrik Sæterhagen, André Pekkola Pacheco, Are Hugo Pripp, Harald Hrubos-Strøm, Costas Papageorgiou, John Munkhaugen, Toril Dammen","doi":"10.5664/jcsm.11656","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>Insomnia affects up to 50% of patients with cardiovascular diseases (CVD) and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known on the effects of CBT-I in patients with established CVD. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with CVD and comorbid insomnia.</p><p><strong>Methods: </strong>Medline, Embase, PsycINFO and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's risk of bias 2 tool) were independently conducted by co-authors. Data were meta-analyzed using random-effects models.</p><p><strong>Results: </strong>In all, 1275 records with five studies fulfilled the inclusion criteria (n=352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity post-treatment (standardized mean difference [SMD] = -0.90, 95%CI: -1.43, -0.37, p < .001), sleep onset latency (SOL), anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (SMD = -0.77, 95%CI: -1.10, -0.45, p < .001) and sleep efficiency (SMD = 0.68, 95%CI: 0.12-1.25, p < .001). We regarded three RCTs as having low risk of bias, and had some concerns with another.</p><p><strong>Conclusions: </strong>Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among CVD patients, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.</p><p><strong>Systematic review registration: </strong>Registry: PROSPERO; Identifier: CRD4202448873; Title: Effects of cognitive behavioral therapy for insomnia in patients with coronary heart disease: A systematic review; URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024488739.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Study objectives: Insomnia affects up to 50% of patients with cardiovascular diseases (CVD) and is associated with poor clinical outcomes. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but little is known on the effects of CBT-I in patients with established CVD. We aimed to investigate the effects of CBT-I on insomnia symptom severity, sleep parameters, and daytime symptoms in patients with CVD and comorbid insomnia.
Methods: Medline, Embase, PsycINFO and ClinicalTrials.gov were searched for randomized controlled and open trials up to December 2023. Study selection, data extraction, and risk of bias assessment (Cochrane's risk of bias 2 tool) were independently conducted by co-authors. Data were meta-analyzed using random-effects models.
Results: In all, 1275 records with five studies fulfilled the inclusion criteria (n=352 patients). Compared with active control groups, CBT-I significantly reduced insomnia severity post-treatment (standardized mean difference [SMD] = -0.90, 95%CI: -1.43, -0.37, p < .001), sleep onset latency (SOL), anxiety, and fatigue. Moreover, CBT-I significantly improved sleep quality (SMD = -0.77, 95%CI: -1.10, -0.45, p < .001) and sleep efficiency (SMD = 0.68, 95%CI: 0.12-1.25, p < .001). We regarded three RCTs as having low risk of bias, and had some concerns with another.
Conclusions: Evidence from our analyses indicated that CBT-I seems to be effective for alleviating insomnia symptoms among CVD patients, largely in line with the results of previous meta-analyses in patients with insomnia. The limited sample size encourages more robust evidence from high-quality, large-scale trials with long-term follow-up.
Systematic review registration: Registry: PROSPERO; Identifier: CRD4202448873; Title: Effects of cognitive behavioral therapy for insomnia in patients with coronary heart disease: A systematic review; URL: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024488739.
期刊介绍：
Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
